New Delhi, Dec 17 (Prensa Latina) India’s Covid-19 vaccine candidate has demonstrated a strong immune response in its first phase of clinical trials, it was learned here Thursday.
The possible Covaxin vaccine, developed by the biotechnology company Bharat Biotech, based in the city of Hyderabad, and the Indian Council of Medical Research, is safe and does not generate serious adverse effects in people of all groups, according to the results of the first phase clinical trial, All India Radio reported.
The Indian Medical Research Council said the vaccine can be stored at 2-8 degrees Celsius, which makes it compatible with the national immunization plan.
Covaxin is one of three candidate vaccines against the SARS-CoV-2 coronavirus pandemic that has been considered for emergency use approval in India by the national drug regulator.
jg / abo / agp / abm